ABVC Live signals | Maximize Profits with Getagraph.com

BUY 97091 min ago

@ $1.300

Issued: 8 Feb 2024 @ 13:07

Return: -16.15%

Previous signal: Feb 7 - 09:30

Previous signal: Sell

Return: -7.80 %

Live Chart Being Loaded With Signals

Commentary (15 Apr 2024 @ 16:00):

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States...

Stats
Today's Volume	218 098
Average Volume	724 287
Market Cap	11.51M
EPS	$0 ( 2024-03-29 )
Next earnings date	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.450
ATR14	$0.00400 (0.37%)

Insider Trading

Date	Person	Action	type
2022-05-20	Jiang Shuling	Buy	Common Stock
2021-08-02	An Chihliang	Sell	Common Stock
2021-08-02	Sakamoto Norimi	Buy
2021-08-02	Odaira Yoshinobu	Sell	Common Stock
2021-08-02	Jiang Tsung Shann	Buy	Common Stock

INSIDER POWER
0.00
Last 77 transactions
Buy: 22 119 096 \| Sell: 9 170 000

Volume Correlation

Long: -0.05 (neutral)

Short: 0.94 (very strong)

Signal:(65.203) Expect same movement, but be aware

AMERICAN BRIVISION Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

AMERICAN BRIVISION Correlation - Currency/Commodity

0.52
( weak )

0.36
( neutral )

0.00
( neutral )

-0.44
( neutral )

AMERICAN BRIVISION Financials

Annual	2023
Revenue:	$152 430
Gross Profit:	$-178 138 (-116.87 %)
EPS:	$-2.43

Q4	2023
Revenue:	$2 165.00
Gross Profit:	$-144 623 (-6 680.05 %)
EPS:	$-0.390

Q3	2023
Revenue:	$15 884.00
Gross Profit:	$-13 730.00 (-86.44 %)
EPS:	$-0.820

Q2	2023
Revenue:	$6 109.00
Gross Profit:	$-66 872.00 (-1 094.65 %)
EPS:	$-0.680

Financial Reports:

No articles found.

AMERICAN BRIVISION

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.